<DOC>
	<DOCNO>NCT02484378</DOCNO>
	<brief_summary>The purpose study assess impact ten intravenous infusion 3 mg/kg CER 001 vs. placebo , give weekly interval ten week , atherosclerotic plaque volume measure coronary IVUS , administer subject present Acute Coronary Syndrome ( ACS ) significant plaque volume .</brief_summary>
	<brief_title>CER-001 Atherosclerosis Regression ACS Trial</brief_title>
	<detailed_description>Subjects require least one epicardial coronary artery suitable IVUS imaging . A suitable target artery IVUS imaging determine baseline stenosis 50 % meeting angiographic inclusion criterion . Subjects meet eligibility criterion randomize receive intravenous infusion CER 001 ( 3 mg/kg ) placebo within 14 day event presentation . Randomized subject return 7 day interval nine additional infusion . A follow IVUS conduct 14 day last infusion . The total study duration randomization follow IVUS complete study range approximately 9 12 week .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Male female great 18 year age Acute coronary syndrome ( myocardial infarction unstable agina ) Angiographic evidence coronary artery disease suitable `` target '' coronary artery IVUS evaluation Females childbearing potential Angiographic evidence &gt; 50 % stenosis leave main artery Uncontrolled diabetes ( HbA1C &gt; 10 % ) Hypertriglyceridemia ( &gt; 500 mg/dL ) Congestive heart failure ( NYHA class III IV ) Ejection fraction &lt; 35 % Uncontrolled hypertension ( SBP &gt; 180 mm Hg ) Known major hematologic , renal , hepatic , metabolic , gastrointestinal endocrine dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ACS</keyword>
	<keyword>IVUS</keyword>
	<keyword>HDL</keyword>
</DOC>